Specimens collected just before or within 15 minutes of the next dose represent the TROUGH levels. Specimens obtained within 15-30 minutes after the end of I.V. infusion or 45-60 minutes after an IM injection or 90 minutes after oral intake represent the PEAK level.

Therapeutic levels:

Peak serum

1.5-2.1 mcg/mL

This test is available for New York patient testing.

Dengue virus, transmitted by mosquitoes, causes dengue fever and dengue hemmorhagic fever in tropical and sub-tropical regions of the world. The detection of dengue virus RNA is based upon reverse transcription of specific conserved dengue virus genomic RNA sequences followed by PCR amplification. Detection probes utilized in the assay have been designed to detect dengue virus subgroups 1 and 3 (DV1/3 probe) as well as subgroups 2 and 4 (DV2/4 probe).

This test is not approved for New York patient testing.

This assay detects both IgG and IgM antibodies against all four Dengue fever virus types. Except for very early IgM responses, the immune response to Dengue fever is not type specific. Therefore, type specific reactions are not reported. As with most serological assays paired testing of acute and convalescent samples is preferred. This is especially important when the acute phase sample is taken within the six days following onset. In most patients, Dengue antibodies are detectable after the sixth day following the onset of symptoms. Crossreactivity with other Flaviviruses is known to occur. The extent and degree of crossreaction varies.

†This test was developed and its performance characteristics determined by Focus Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

This test is approved for New York patient testing.

Low dengue virus (DV) IgG avidity indicates acute primary DV infection. High DV IgG avidity for a specimen collected within 30 days of disease onset indicates acute secondary DV infection, and an increased risk for dengue hemorrhagic fever.

This test is approved for New York patient testing.

This assay detects IgG antibodies against all four Dengue fever virus types. Except for very early IgM responses, the immune response to Dengue fever is not type specific. Therefore, type specific reactions are not reported. As with most serological assays paired testing of acute and convalescent samples is preferred. This is especially important when the acute phase sample is taken within the six days following onset. In most patients, Dengue antibodies are detectable after the sixth day following the onset of symptoms. Crossreactivity with other Flaviviruses is known to occur. The extent and degree of crossreaction varies.

†This test was developed and its performance characteristics determined by Focus Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

This test is approved for New York patient testing.

This assay detects IgM antibodies against all four Dengue fever virus types. Except for very early IgM responses, the immune response to Dengue fever is not type specific. Therefore, type specific reactions are not reported. As with most serological assays paired testing of acute and convalescent samples is preferred. This is especially important when the acute phase sample is taken within the six days following onset. In most patients, Dengue antibodies are detectable after the sixth day following the onset of symptoms. Crossreactivity with other Flaviviruses is known to occur. The extent and degree of crossreaction varies.

†This test was developed and its performance characteristics determined by Focus Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

This test is approved for New York patient testing.

Specimens collected just before or within 15 minutes of the next dose represent the TROUGH levels. Specimens obtained within 15-30 minutes after the end of I.V. infusion or 45-60 minutes after an IM injection or 90 minutes after oral intake represent the PEAK level.

This test is available for New York patient testing.

• Chronic Fatigue Immune Dysfunction Syndrome Panel
• Chronic Fatigue Syndrome Panel III
• Chronic Fatigue Syndrome Viral Panel

A minimal four-fold increase between pre-immunization and post-immunization sera is considered a normal response to diphtheria toxoid. Antitoxoid levels >=0.01 IU/mL are considered protective. See Focus Unit Code 4415 for parallel testing.

This test is approved for New York patient testing.

 Vaccine Response Testing

• Antimicrobial Susceptibility, Streptococcus pneumoniae, MIC Panel
• Antimicrobial Susceptibility, Streptococcus, MIC and MBC Panel
• Streptococcus pneumoniae IgG, Pre- and Post-Vaccination (12 Serotypes)
• Streptococcus pneumoniae IgG, Pre- and Post-Vaccination (14 Serotypes)
• Streptococcus pneumoniae IgG, Pre- and Post-Vaccination (6 Serotypes)
• Streptococcus pneumoniae IgG, Pre- and Post-Vaccination (7 Serotypes)

Approximately 60% of Systemic Lupus Erythematosis (SLE) patients have detectable levels of dsDNA antibody.

This test is approved for New York patient testing.

This assay uses Crithidia lucilliae as substrate, and is highly specific for dsDNA antibody. Approximately 60% of Systemic Lupus Erythematosis (SLE) patients have detectable levels of dsDNA antibody.

This test is approved for New York patient testing.